KRONEMED
The key tool at our disposal to enhance the management of many illnesses is fundamental research. A wide range of treatments and medications are available to doctors and patients today that can enhance patients’ prognoses and quality of life. KroneMED encourages the sharing of information and skills.
Founded in June 2023, KroneMED is a service company that promotes and manages clinical trials in Italy, especially in the field of cancer treatment.
Precision Medicine
The term “precision” has significant importance within the field of oncology. Every individual patient has unique qualities that distinguish them from others, necessitating a therapeutic approach that is highly personalized and customized. Therefore, the concept of precision oncology emerges as a means to combat tumors by employing strategies that are tailored to the specific characteristics of each individual case. The primary goal is to enhance the efficacy and activity of cancer treatments while simultaneously prioritizing the quality of life for patients.
Histological model
The recent authorization of molecules with indications referred to be “agnostic” is contributing to the establishment of a novel paradigm known as the “mutational” model. This phenomenon represents a significant scientific and cultural transformation, which is expected to steer us away from the conventional oncology approach that focuses on the damaged organs or histology, as shown in the classical “histological model”.
Genomic profile
he primary focus of the novel procedure is the utilization of genomic profiling, which involves identifying mutations or molecular alterations that significantly contribute to the formation of neoplasms, commonly referred to as “drivers.” This identification process serves as the basis for selecting appropriate drugs and determining the therapeutic approach, irrespective of the tumor’s location, the patient’s age, or gender.
Mutational model
In brief, the histological model of therapeutic indication relies on the examination of the tumor’s histology, while the mutational model incorporates genomic profiling while also acknowledging the significance of morphological and histological data.
According to the mutational model, new oncological drugs can potentially provide an added therapeutic benefit, particularly for rare tumors and patients who have already undergone all available treatment options. This assertion is supported by specific scientific evidence and is in accordance with the necessary regulatory approvals for drug usage.
Communication in the scientific field is essential for generating valuable content and proving the scientific value of products in a real-world setting.
KroneMED provides planning, implementation, administration, and support services to organizations primarily in the clinical, medical, pharmacological, biotechnological, and scientific research industries.
KroneMED encourages academic research for clinical investigation.
Collaboration with public institutions may result in significant advances in finding innovative therapeutic targets, thereby helping patients.
We would aim to provide resources, technology, and knowledge in areas like as medication development, diagnostics, and novel technologies that help speed the translation of research discoveries into practical applications.
Highlights: We are seeking collaboration with hospitals and clinics in the field of Personalized Medicine in Italy
Cancer Immunotherapy
Using the immune system to combat cancer is how cancer immunotherapy functions. This implies that immune cells rather than cancer cells are the main subject. Cancer immunotherapy aims to improve or restore the immune system’s capacity to identify and destroy cancer cells. The efficacy of this treatment approach depends on how well the immune cells eradicate the tumor cells. Although it is challenging to predict whether the immune system can successfully combat big tumor masses, evidence suggests that lowering tumor burden enhances the chance of good immunotherapy results.
Clinical trials
The scientific studies of the human species are referred to by this word. The development of medical knowledge takes place in little, gradual steps. It is crucial to show that a therapy, such as a medicine, technology, vaccination, surgery, or medical aid, is safe and effective before introducing it. Assessing both the possible hazards and rewards of the intervention falls under this category. The recommendation for the use of the treatment in current clinical practice may only be made when the risk-benefit ratio is good.
Clinical trials are carried out to ascertain if and by how much a novel diagnostic or treatment approach is superior to those presently in use.
Multi-omics analysis
It is possible that the generation of high-dimensional data, which can be obtained using a variety of applications from samples that are either healthy or pathological, as well as from a correlation between the data, will accelerate the process of discovery, improve our understanding of complicated diseases, and contribute to the future prospects of omics sciences. Within this framework are included activities such as the identification of diagnostic biomarkers and the investigation of potential treatment targets.
From the Laboratory to Personalized Medicine
Pathology Lab
Using the results of a biopsy or the tissue that was removed during surgery, the pathologist will identify the disease process as well as the severity of the condition. Under a microscope, pathologists examine very thin slices of the lesion in order to make their diagnoses. This is done in every situation. In addition, pathologists frequently make use of a variety of specific molecular methods in order to improve the accuracy of their diagnosis and better anticipate how a disease would respond to a variety of treatments. The pathologist is therefore able to direct any following therapy that the patient might require.
Analyzes
The combining of two or more omics datasets for the goal of facilitating the analysis, visualization, and interpretation of data for the purpose of finding the processes of a particular biological activity is referred to as multi-omics or pan-omics. The use of these analyses in the field of biomedical research has resulted in the acquisition of fresh information on biological occurrences and procedures.
Therapies
The field of genetics is intimately connected to personalized medicine. Genes are segments of DNA that supply instructions for the body to follow in order to manufacture proteins and carry out other essential activities. These genetic instructions are written in four separate bases, each of which only contains four chemical “letters” or bases.
People frequently have genes that differ from one another slightly. Bases can be altered, substituted, or left out entirely. The majority of these variants have just a marginal bearing on one’s state of health. On the other hand, some people may create abnormal proteins, which might put them at a greater risk of developing certain diseases. Some variances can alter how effectively a medicine works, while others can cause the treatment to have adverse effects that are unique to each individual patient.
E-learning
Continuous updating enables you to keep up with the times, optimize processes, remain apprised of the most recent news, and comprehend how technology, artificial intelligence, and technological advancement can impact the quality of your work
Insights
The exchange of information and experiences, as well as plans for corporate development in knowledge and awareness, as well as preparations for training and mentoring. The most important aspect of personal development is paying attention to the methods you presently use and making adjustments to those methods in order to get better results
Training
There is open communication between the University and the world of business and technology; as a result, new possibilities come up as a result of collaborative initiatives; the biotechnology industry and scientific research continue to go forward together in locating new medical frontiers
Do you wish to get further information?
Get in touch with us, and we will offer you information on our collaboration in addition to the types of clinical trial services we can provide in Italy and Europe.